MD Anderson Cancer Center notes that evidence suggests GLP-1 agonists like semaglutide may decrease overall cancer risk beyond just the benefits of weight loss
What started with semaglutide quickly expanded to tirzepatide, and now retatrutide is generating attention as the next potential breakthrough in obesity treatment
With single-unit purchasing, the risk of a supply break grows with each repeat transaction
Where it works: Adipose tissue (fat cells): Reduces inflammation and may improve fat metabolism Pancreas: Works alongside GLP-1 to enhance insulin secretion Brain: May contribute to appetite regulation (research ongoing) Weight loss contribution: When GIP is added to GLP-1 (as in tirzepatide), weight loss increases from ~15% to ~22%
A cell marked n/a means the dose in that column exceeds the total amount of retatrutide in the vial, so it is physically impossible to draw
While your body's natural GLP-1 has a short lifespan of just 2 to 3 minutes before being broken down, it performs essential metabolic functions that help maintain glucose homeostasis
